免疫介导坏死性肌病命名与缩写异质性:呼吁标准化
该范围综述纳入626篇英文文献,分析1974年至2023年免疫介导坏死性肌病(IMNM)命名与缩写的多样性及趋势。结果显示拼写、后缀、前缀及缩写均存在异质性,2010年后逐渐向IMNM标准化形式趋同,但残余变异仍存,需统一术语。
要点
- 2010年后「necrotizing」拼写占主导(497次 vs 66次),「myopathy」后缀远超「myositis」(487 vs 44)。
- 「immune-mediated」前缀在2010年后成为主流(366次),远超「autoimmune」(91次)。
- 缩写IMNM自2011年出现后占主导(80%),但抗体命名(7%)和他汀相关描述(11%)仍少见。
核心结论
- IMNM命名经历了明显演变并逐渐形成共识,但标准化后仍存在残余变异,需统一术语以促进研究、合作和临床诊疗。
研究设计与样本
- 范围综述,检索1974年11月至2023年12月的英文文献,共识别1236篇,纳入626篇,覆盖42个国家,按发表年份、地区和设计分类,使用SPSS进行描述性统计与趋势分析。
主要发现
- 拼写方面「necrotizing」被提及497次,「necrotising」66次,2010年后「z」形式使用急剧上升(463 vs 60)。
- 疾病后缀「myopathy」在2010年后远超「myositis」(487 vs 44)。
- 前缀「immune-mediated」在2010年后占主导(366次),「autoimmune」91次。
- 基于抗体的命名少见(7%),他汀相关描述占11%。
- 缩写自2011年出现,IMNM占80%,NAM占13%,NM占6%。
关键数值与推荐
- 2010年后「necrotizing」拼写463次,「necrotising」60次。
- 2010年后「myopathy」后缀487次,「myositis」44次。
- 2010年后「immune-mediated」前缀366次,「autoimmune」91次。
- 缩写IMNM占80%,NAM占13%,NM占6%。
临床怎么用
- 临床与研究应统一采用「immune-mediated necrotizing myopathy(IMNM)」标准化命名,避免因术语异质性影响研究可比性、临床试验设计和患者诊疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune-mediated necrotizing myopathy (IMNM) is a distinct subtype of idiopathic inflammatory myopathies (IIMs). Despite its increasing recognition, considerable variability persists in its nomenclature, posing challenges for research comparability, clinical trial design, and patient care. METHODS: We conducted a scoping review of English-language publications from November 1974 to December 2023 to assess the diversity and trends in IMNM nomenclature and abbreviations. Articles were screened for IMNM terminology and abbreviations, and categorized by publication year, region, and study design. Descriptive statistics with temporal/geographic trend analyses were performed using SPSS. RESULTS: Of 1236 articles identified, 626 met inclusion criteria, spanning 42 countries. Marked heterogeneity in terminology was observed. Regarding spelling, "necrotizing" (with "z") predominated (497 mentions) compared to "necrotising" (66 mentions), particularly after 2010 when usage of the "z" form rose sharply (463 vs. 60, respectively). For disease suffix, "myopathy" overwhelmingly replaced "myositis" in recent years (487 vs. 44 post-2010). Prefix terminology also evolved: "immune-mediated" became the dominant prefix (366 mentions post-2010) compared to "autoimmune" (91 mentions). Longitudinal analysis demonstrated that prior to 2010, terminology was inconsistent, but from 2010 onwards, coinciding with the ENMC classification, publications increasingly converged toward the standardized form immune-mediated necrotizing myopathy (IMNM). Antibody-based naming remained uncommon (7 %), and statin-associated descriptors were reported in 11 %. Abbreviations emerged in 2011, with IMNM now dominant (80 %) compared to NAM (13 %) and NM (6 %). CONCLUSION: This review highlights a clear evolution and gradual consensus in IMNM nomenclature. Despite progress toward standardization, residual variability persists, underscoring the need for unified terminology to advance research, collaboration, and clinical care.
引用
- Almackenzie M, Bhowmick N, Bhangoo G, et al. Nomenclature and abbreviation heterogeneity in immune-mediated necrotizing myopathy: A call for standardization. Semin Arthritis Rheum. 2026. PMID: 41780350. doi:10.1016/j.semarthrit.2026.152950
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。